The findings, which appeared today in JAMA Network Open, are strong evidence that buprenorphine, a medication approved by the U.S. Food and Drug Administration to treat opioid use disorder, can be ...

Please provide your email address to receive an email when new articles are posted on . The study included 227 individuals with OUD given CAM2038 either on weekly or monthly basis. The treatment was ...

A seven-day, extended-release version of buprenorphine — a treatment for opioid use disorder (OUD) that can reduce opioid use and overdose deaths — is safe and effective for people with OUD ...

Unimaginable pain and restlessness. Vomiting so frequent and forceful that it can perforate the esophagus. Blood pressure and heart rate so high that they damage the heart. Sweating that drenches ...

Extended-release 7-day injectable buprenorphine was safe and tolerable for most patients who had minimal-to-mild opioid withdrawal, a nonrandomized trial found. Among 100 adult patients with ...

More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.

Buprenorphine, an evidence-based treatment for opioid use disorder, is currently underprescribed because of concerns that it can cause ‘precipitated withdrawal’, in which the first dose causes sudden, ...

Twenty-four percent of US adolescent treatment centers do not use a “lifesaving” medication. An article appeared today in the Journal of the American Medical Association titled “Treatments Used Among ...